Andrew Joseph , 2025-05-14 08:25:00
Contents
LONDON — GSK said Wednesday it would purchase an experimental liver disease medicine from Boston Pharmaceuticals for $1.2 billion upfront, seeking to build up its pipeline of future medicines.
The drug, called efimosfermin, is in development to treat a liver condition called MASH, an indication that a number of drugmakers are pursuing. The once-monthly drug is also being considered as a treatment for alcohol-related liver disease.
The deal for efimosfermin, which GSK described as ready for Phase 3 studies, includes another $800 million if certain milestones are met.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
